Targeted therapy and immunotherapy for recurrent liver cancer
10.19538/j.cjps.issn1005-2208.2019.10.13
- Author:
Ting-hui MAO
1
;
Gang WU
1
Author Information
1. Department of Hepatobiliary and Transplantation Surgery,the First Hospital of China Medical University Shenyang 110001,China
- Publication Type:Journal Article
- Keywords:
hepatocellular carcinoma(HCC);
recurrent liver cancer;
targeted therapy;
immunotherapy
- From:
Chinese Journal of Practical Surgery
2019;39(10):1048-1051
- CountryChina
- Language:Chinese
-
Abstract:
The recurrence and metastasis rate of hepatocellular carcinoma(HCC) is high after operation,and more than 50% of HCC patients will eventually receive systemic treatment. There is a lack of systemic treatment for advanced liver cancer,so that Sorafenib is the only first-line therapeutic drug in the past ten years. Recently,positive results have been obtained in the III phase clinical trials of lenvatinib,regorafenib,cabozantinib and Ramucirumab,and anticancer effect of the immunotherapy of liver cancer shows gratifying,but there are still some shortcomings,such as low objective response rate and lack of effective clinical biomarkers. The antitumor effect of immunotherapy-based combined therapy is more satisfactory than that of single drug without more serious side effects in I/II phase clinical trials,which means immunotherapy-based combined therapy should be the future treatment strategy.
